Biopharmx Corp (NYSEAMERICAN:BPMX) major shareholder Vivo Capital Viii, Llc sold 296,394 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $0.20, for a total transaction of $59,278.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Biopharmx Corp (NYSEAMERICAN BPMX) remained flat at $$0.19 during trading on Thursday. The stock had a trading volume of 679,100 shares, compared to its average volume of 1,349,153. Biopharmx Corp has a 52-week low of $0.16 and a 52-week high of $0.90.
Biopharmx Corp (NYSEAMERICAN:BPMX) last issued its quarterly earnings data on Wednesday, September 13th. The biotechnology company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.